Phagenesis appoints chairman and CEO to take new dysphagia treatment to market
This article was originally published in Clinica
Phagenesis, a UK company developing a neurostimulation technology to treat dysphagia caused by stroke, has appointed Henry Hyde-Thomson chairman and Daniel Green CEO. Mr Hyde-Thomson is a serial entrepreneur and is the founder and chairman of UK-based private equity firm AngloScientific. Mr Green was most recently co-founder and CEO of regenerative medicine firm RepRegen. Both will lead Phagenesis’ efforts in taking its first dysphagia treatment product to market. Dysphagia is the inability to swallow properly; at least 50% of stroke patients are affected by this condition. Phagenesis, which was spun out of the University of Manchester in 2007, has developed a device that delivers electrical pulses to the throat region. These pulses stimulate the nerve cells that run directly to the part of the brain which controls swallowing and helps to restore this function. Other causes include diseases like multiple sclerosis, Parkinson’s disease, Alzheimer’s and motor neurone disease.